<p>根據 4 月 25 日的文件，Amplitude Surgical 75.4% 的股東與 Zydus Lifesciences 簽署了出售大部分股份的協議，價格為每股 6.25 歐元。</p>
<p>考慮到之前的兩項股份購買協議，這家印度製藥公司已承諾收購法國骨科技術公司 85.6% 的股份。該區塊交易預計將在第三季度完成，前提是滿足交割條件。</p>
<p>由於其他少數股東也承諾將其股份進行要約，Zydus 預計將收購超過 90% 的公司股份，並實施剩餘股份的強制收購程序。</p>

<p>Amplitude Surgical 75.4% 的股東已同意以每股 6.25 歐元的價格將其多數股權出售給 Zydus Lifesciences。包括之前的協議，Zydus 將收購這家法國骨科公司的 85.6% 股權。該交易預計將在第三季度完成，具體取決於相關條件。隨着其他少數股東也同意出售，Zydus 預計將收購超過 90% 的股份，並啓動對剩餘股份的強制收購</p>

<p>Holders of 75.4% of Amplitude Surgical's  shares entered an agreement with Zydus Lifesciences for the sale of the majority stake for 6.25 euros apiece, according to an April 25 filing.</p>
<div class="lb-trans"><p>根據 4 月 25 日的文件，Amplitude Surgical 75.4% 的股東與 Zydus Lifesciences 簽署了出售大部分股份的協議，價格為每股 6.25 歐元。</p>
</div><p>Counting two prior share purchase agreements, the Indian pharmaceutical company has committed to buying 85.6% of the French orthopedic technology company. The block deal is expected to close in the third quarter, subject to the satisfaction of closing conditions.</p>
<div class="lb-trans"><p>考慮到之前的兩項股份購買協議，這家印度製藥公司已承諾收購法國骨科技術公司 85.6% 的股份。該區塊交易預計將在第三季度完成，前提是滿足交割條件。</p>
</div><p>As other minority shareholders of Amplitude have also committed to tender their shares, Zydus expects to acquire over 90% of the company and implement a squeeze-out procedure for the remaining shares.</p>
<div class="lb-trans"><p>由於其他少數股東也承諾將其股份進行要約，Zydus 預計將收購超過 90% 的公司股份，並實施剩餘股份的強制收購程序。</p>
</div>

Amplitude Surgical 的股東達成協議，將 75.4% 的股權出售給 Zydus Lifesciences